{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:21:13Z","timestamp":1780471273009,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To describe the frequency of neutropenia and Felty syndrome in patients with rheumatoid arthritis (RA) attended in routine clinical practice. Methods: We selected by randomization a sample of 270 RA patients attended from January 2014 to November 2022. Demographic, clinical, and neutropenia-related variables were collected from the electronic medical records. Neutropenia was defined as having an absolute neutrophil count (ANC) of less than 1500\/mm3 once, and acute if it persisted for &lt;3 months. Felty syndrome was defined as RA-related neutropenia, rheumatoid factor (RF) and\/or anti citrullinated protein antibody (ACPA) positivity. Results: We found 50 patients who had at least one neutropenia episode, with an incidence of 18.5% (14.0\u201325.6%). Most were women, with age (mean, p25\u2013p75) at the time of neutropenia of 61.5 (57.4\u201369.3) years, 85% RF+ and 76% ACPA+. The demographic and RA characteristics of patients with and without neutropenia were very similar, except for sex: most patients with neutropenia were women. The 50 patients had 99 episodes of neutropenia; 59% were acute. The lower ANC was 1240 (1000\u20131395) mm3, and most of the episodes were mild (74%). In 32% of cases, there was other cytopenia. The RA activity measured by DAS28 in patients with neutropenia was low, at 2.18 (1.75\u20132.97). A total of 82 of 99 neutropenia episodes were related to DMARDs, 60% to Anti-IL6 drugs in monotherapy, 13% to RA activity, 3% to infectious diseases and 1% to hematologic malignancy. There were five (1.8%) cases with Felty syndrome, but only one woman with the classic combination of RA, positivity of autoantibodies (RF and ACPA), neutropenia and splenomegaly. Conclusions: In the 21st century, neutropenia in RA patients is most commonly related to biologics, mostly IL6 inhibitors and methotrexate. Episodes are mild, acute, with low RA activity, and associated with severe infections in few cases. Felty syndrome is rare.<\/jats:p>","DOI":"10.3390\/jcm13247677","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:46:02Z","timestamp":1734407162000},"page":"7677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neutropenia and Felty Syndrome in the Twenty-First Century: Redefining Ancient Concepts in Rheumatoid Arthritis Patients"],"prefix":"10.3390","volume":"13","author":[{"given":"Jorge Luis","family":"Rodas Flores","sequence":"first","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-3610","authenticated-orcid":false,"given":"Blanca","family":"Hern\u00e1ndez-Cruz","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8638-8680","authenticated-orcid":false,"given":"V\u00edctor","family":"S\u00e1nchez-Margalet","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry and Molecular Biology and Immunology, School of Medicine, Virgen Macarena University Hospital, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez-Reboul Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Fern\u00e1ndez Panadero","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracia","family":"Moral Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Javier","family":"P\u00e9rez Venegas","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Virgen Macarena University Hospital, Health Service of Andalucian, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e000739","DOI":"10.1136\/rmdopen-2018-000739","article-title":"Neutropaenia in early rheumatoid arthritis: Frequency, predicting factors, natural history and outcome","volume":"4","author":"Fragoulis","year":"2018","journal-title":"RMD Open."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2015.01.005","article-title":"Management of neutropenia in patients with rheumatoid arthritis","volume":"82","author":"Lazaro","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/kez344","article-title":"Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: A population-based study","volume":"59","author":"Nikiphorou","year":"2020","journal-title":"Rheumatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.semarthrit.2012.08.001","article-title":"Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: Study of three cohorts (ESPOIR, VErA, and Brittany)","volume":"42","author":"Marhadour","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/ard.36.6.500","article-title":"Felty\u2019s syndrome. Clinical and serological analysis of 34 cases","volume":"36","author":"Sienknecht","year":"1977","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wegscheider, C., Ferincz, V., Sch\u00f6ls, K., and Maieron, A. (2023). Felty\u2019s syndrome. Front. Med., 17.","DOI":"10.3389\/fmed.2023.1238405"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_8","unstructured":"(2024, November 17). Available online: https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_25_1_Spanish.pdf."},{"key":"ref_9","unstructured":"(2024, November 17). Available online: https:\/\/www.sspa.juntadeandalucia.es\/servicioandaluzdesalud\/sites\/default\/files\/sincfiles\/wsas-media-pdf_publicacion\/2020\/Enfermedades_Sangre.pdf."},{"key":"ref_10","unstructured":"(2024, October 12). Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/108492007\/FT_108492007.html."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105510","DOI":"10.1016\/j.jbspin.2022.105510","article-title":"Clinical significance of tocilizumab-related neutropenia in patients with rheumatoid arthritis","volume":"90","author":"Kim","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"ref_14","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: Pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2017","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/key361","article-title":"Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis","volume":"58","author":"Emery","year":"2019","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/ard.2006.056176","article-title":"Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis","volume":"65","author":"Rajakulendran","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/acr.20037","article-title":"Neutropenia in patients receiving anti-tumor necrosis factor therapy","volume":"62","author":"Hastings","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e000034","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: Data from the AutoImmunity and Rituximab registry","volume":"30","author":"Salmon","year":"2015","journal-title":"RMD Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102227","DOI":"10.1016\/j.coph.2022.102227","article-title":"Treatment of early rheumatoid arthritis: Methotrexate and beyond","volume":"64","author":"Baker","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/kez168","article-title":"Transaminitis and neutropenia are rare in patients on methotrexate: Evidence from a large cohort of inflammatory arthritis patients","volume":"58","author":"Malley","year":"2019","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M19-3369","article-title":"Adverse Effects of Low-Dose Methotrexate: A Randomized Trial","volume":"172","author":"Solomon","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard-2022-222784","article-title":"Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update","volume":"82","author":"Aletaha","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2021025","DOI":"10.4084\/mjhid.2021.025","article-title":"How I Treat Febrile Neutropenia","volume":"13","author":"Nucci","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_27","first-page":"20499361221138346","article-title":"Approach to fever in patients with neutropenia: A review of diagnosis and management","volume":"9","author":"Keck","year":"2022","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MJT.0b013e318164bf32","article-title":"Rituximab is useful in the treatment of Felty\u2019s syndrome","volume":"15","author":"Chandra","year":"2008","journal-title":"Am. J. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/03009742.2017.1334816","article-title":"Successful treatment of refractory neutropenia in Felty\u2019s syndrome with rituximab","volume":"47","author":"Wang","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-020-04588-3","article-title":"Tocilizumab treatment in Felty\u2019s syndrome","volume":"40","author":"Li","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2004.032110","article-title":"Etanercept in treatment of Felty\u2019s syndrome","volume":"64","author":"Ghavami","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","first-page":"e46086","article-title":"The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis","volume":"15","author":"Chin","year":"2023","journal-title":"Cureus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/imj.15180","article-title":"The role of intravenous immunoglobulin in treatment of refractory Felty syndrome c","volume":"51","author":"Jeong","year":"2021","journal-title":"Intern. Med. J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:53:28Z","timestamp":1760115208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":33,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247677"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247677","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}